08:00 , Jan 14, 2013 |  BioCentury  |  Finance

Darwin's delight

The biotech ecosystem looks healthy moving into 2013. With the space above $1 billion more than replenished in 2012, mid-cap names have money to create their own tier-jumping stories this year, while investors see natural...
08:00 , Dec 17, 2012 |  BC Week In Review  |  Financial News

Venaxis financial update

Venaxis (formerly AspenBio Pharma Inc. ) raised $612,990 through the sale of 291,900 shares to cover the overallotment from its Nov. 14 follow-on, bringing the total raised to $4.7 million. The company, which closed Friday...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Financial News

AspenBio completes follow-on

AspenBio Pharma Inc. (NASDAQ:APPY), Castle Rock, Colo.   Business: Veterinary, Diagnostic, Supply/Service   Date completed: 11/14/12   Type: Follow-on   Raised: $3.1 million   Shares: 1.5 million   Price: $2.10   Shares after offering: 9.2...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Company News

AspenBio diagnostic news

AspenBio said that four directors resigned from its board as part of a restructuring that began in mid-2011 to focus on developing its AppyScore appendicitis test. The resignations include Douglas Hepler, Michael Merson, Mark Ratain...
07:00 , Oct 1, 2012 |  BioCentury  |  Finance

3Q Stock Wrap-Up: Back in black

Large cap biotechs stormed back after a weak 2Q12 to post a 7% gain for a third quarter in which every market cap segment finished in the black, albeit just barely for the micro-caps. For...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Company News

AspenBio management update

AspenBio Pharma Inc. (NASDAQ:APPY), Castle Rock, Colo.   Business: Veterinary, Diagnostic, Supply/Service   Hired: Lyndal Hesterberg to lead product development of AspenBio's AppyScore , formerly chief technology officer of Crescendo Bioscience Inc.  ...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Company News

AspenBio, Ceva Sante Animale S.A. deal

AspenBio granted animal health company Ceva exclusive, worldwide rights to develop and commercialize luteinizing hormone (LH) products and follicle stimulating hormone (FSH) products using AspenBio's single chain reproductive hormone technology for bovine, equine and swine....
07:00 , Jul 16, 2012 |  BC Week In Review  |  Financial News

AspenBio financial update

AspenBio received notice from NASDAQ that it regained compliance with the $1 minimum bid requirement and the minimum $2.5 million in stockholders' equity requirement for continued listing. AspenBio Pharma Inc. (NASDAQ: APPY), Castle Rock, Colo....
07:00 , Jul 2, 2012 |  BioCentury  |  Finance

3Q Financial Markets Preview: Avoiding burnout

A slew of milestones through year end combined with last quarter's outperformance have investors hopeful that the biotech sector can continue to fend off a dreary macroeconomic environment and weakness in the broader markets. Buysiders...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Financial News

AspenBio completes follow-on

AspenBio Pharma Inc. (NASDAQ: APPY), Castle Rock, Colo.   Business: Veterinary, Diagnostic, Supply/Service   Date completed: 6/20/12   Type: Follow-on   Raised: $12.2 million   Shares: 6.1 million   Price: $2   Shares after offering:...